Although NT-proBNP is the preferred biomarker for heart failure (HF), a number of studies have suggested that NT-proBNP is also a risk marker to predict major adverse cardiovascular events (MACE) in the general population and in patients with CAD (7–9). This evidence concerns the gene NPPB and hydrops fetalis.